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The first step in hit optimization is the identification of the pharmacophore, which is 
normally achieved by deconstruction of the hit molecule to generate “deletion ana-
logues.” In silico fragmentation approaches often focus on the generation of small 
fragments that do not describe properly the fragment space associated to the deletion 
analogues. We present significant modifications to the molecular fragmentation pro-
gramme molBLOCKS, which allows the exhaustive sampling of the fragment space 
associated with a molecule to generate all possible molecular fragments. This gener-
ates larger fragments, by combining the smallest fragments. Additionally, it has been 
modified to deal with the problem of changing pharmacophoric properties through 
fragmentation, by highlighting bond cuts. The modified molBLOCKS programme 
was used on a set of drug compounds, where it generated more unique fragments 
than standard fragmentation approaches by increasing the number of fragments de-
rived per compound. This fragment set was found to be more diverse than those 
generated by standard fragmentation programmes and was relevant to drug discovery 
as it contains the key fragments representing the pharmacophoric elements associ-
ated with ligand recognition. The use of dummy atoms to highlight bond cuts further 
increases the information content of fragments by visualizing their previous bonding 
pattern.
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1 |  INTRODUCTION
Fragment- based drug discovery (FBDD) has become an in-
creasingly common and powerful tool in the drug discovery 
process.[1–3] FBDD is driven by two concepts that explain 
its use and the reason for its success. Chemical space can 
be probed more efficiently using a library of small frag-
ments rather than larger molecules. With decreasing size 
of the molecules, the number of possible molecules in the 
chemical space decreases as well in an exponential manner. 
Therefore, a collection of low molecular weight molecules 
can cover more diversity of chemical space than a more 
conventional lead- or drug- like library, containing a similar 
number of compounds.[4–7] Moreover, the hit rate for screen-
ing fragments should be higher as a small molecule has a 
higher probability of binding in a receptor without unfavor-
able interactions.[1,6] Although the overall potency is typi-
cally smaller than for larger molecules, the ligand efficiency 
(binding efficiency per heavy atom) can be much higher.[5,7,8] 
Once suitable fragments are identified, they can be optimized 
by merging, linking or growing to generate drug leads.[1,7,9] 
Care has to be taken to keep the optimum interaction between 
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
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the core- fragment and protein as the fragment is grown to 
make a more potent compound. FBDD has been applied to 
a wide range of targets and in the context of different dis-
eases.[10] One of the first success stories was the approval of 
Vemurafenib, a B- Raf kinase inhibitor, considered to be the 
first molecule developed from a FBDD programme to reach 
FDA approval and the market.[11] However, FBDD is still not 
an integral part of drug discovery efforts to target all disease 
areas; one of the key requirements is to be able to rapidly 
generate cocrystal structures of the protein and the fragments 
as they are optimized.[12]
The first step of FBDD is the construction of a fragment 
library. One approach for fragment library design is to make 
use of known chemical and biological data and to deconstruct 
ligands into those fragments that most likely are responsi-
ble for the bioactivity, that is the key pharmacophores of 
the ligands.[2] For example, a fragment library derived from 
known ligands was used to generate two receptor- positive 
allosteric modulators with enhanced potency for preventing 
neuroapoptosis.[13] A library for screening should be diverse 
and of sufficient size to cover as much chemical space as 
possible. Libraries are selected based on the physicochemi-
cal properties of fragments; typically, the rule- of- three[14] is 
used, which takes account of molecular weight, lipophilic-
ity (clogP), numbers of hydrogen bond donors and accep-
tors. High aqueous solubility is also critical for a fragment 
library.[2,5] Reactive and toxic functional groups should also 
be avoided. To determine fragment properties and coverage 
of chemical space, fragment libraries are typically generated 
virtually at first.
One method to generate fragment libraries is by fragmen-
tation of a library of larger molecules (e.g., drugs or natural 
products) that have biological activities. There are a few pro-
grammes available that apply different fragmentation rules to 
deconstruct ligands into smaller molecules. One of the most 
popular fragmentation methods is the retrosynthetic com-
binatorial analysis procedure (RECAP) developed in GSK 
which generates fragments by breaking bonds formed by 
chemical reactions such as amide, amine and ester.[15] Several 
implementations of RECAP can be found in commercial 
programmes: the fragmenter provided by chemaxon (www.
chemaxon.com); the fragment searching and analogue design 
tool BROOD distributed by OpenEye (www.eyesopen.com/
brood); and the open- source RDKit library (www.rdkit.org). 
The latter also includes an implementation of the “break-
ing of retrosynthetically interesting chemical substructures” 
(BRICS) fragmentation that covers a more elaborated set of 
fragmentation rules along synthetically accessible bonds and 
generates more fragments than RECAP.[16]
Another approach for fragment generation is to use 
PUG SOAP, a web tool for the PubChem database[17] and 
its functionality. Ligand substructures can be derived using 
the PubChem superstructure search function in PUG SOAP. 
The derived fragments are substructures of molecules regis-
tered in PubChem; therefore, the fragment space generated is 
strongly biased to what is in PubChem at any time. In a recent 
publication, Firth et al.[18] use SynDir, a fragmentation pro-
gramme applying ordered set of rules, to generate a fragment 
library of synthetic fragments.
In addition to these approaches, Ghersi and Singh re-
cently published a suite of programmes called molBLOCKS 
for breaking down molecules and analysis of the resulting 
fragments.[19] The open- source programme fragments mol-
ecules according to a set of fragmentation rules that are de-
fined using the SMARTS notation. The fragmentation rules 
RECAP, BRICS and CCQ (cleaving a bond between two car-
bon atoms of which at least one is connected to a heteroatom) 
are already implemented, and an additional feature allows the 
user to easily expand these rules and define new ones appli-
cable to different compound spaces. Then, a second program 
called “analyze” can be applied to cluster the resulting frag-
ments and detect statistically enriched fragments.[19] These 
functionalities and the ability to customize the algorithm 
make molBLOCKS an attractive tool to analyze the fragment 
spaces derived by ligands having different bioactivities.
The computational approaches described above have been 
designed to fragment molecules according to synthetic acces-
sibility. Another important consideration when fragmenting 
molecules is capturing the pharmacophore(s) present in the 
parent molecules. The pharmacophoric elements of a com-
pound are the chemical features of the molecule responsible 
for the recognition event of the molecule by its biological tar-
get. Yet, one disadvantage of most fragmentation approaches 
is that the fragmentation can break bonds that might be part 
of a pharmacophore altering its very nature. For example, an 
amide group, acting as both an H- bond donor and H- bond 
acceptor, defines a very specific pharmacophore. However, 
the amide group is normally cleaved during fragmentation 
as synthetically it will be made by coupling a carboxylic acid 
with an amine, neither of which retains the pharmacophoric 
pattern of the amide.
In this paper, we present a modified version of the mol-
BLOCKS programme suite[19] developed to exhaustively 
generate all possible fragments related to a given compound 
and to account for the limitations of current fragmentation 
programs. The fragmentation method currently implemented 
in molBLOCKS will result in a set of building blocks that 
can be used to synthetically access the parent compound by 
following a set of conventional chemical reactions coded in 
the fragmentation rules. As we are interested in capturing 
the pharmacophore content of a given molecule, we worked 
on the development of a tool to generate smaller fragments 
containing different combinations of the pharmacophoric el-
ements present on the parent compound. Therefore, the code 
of the “fragment” programme of molBLOCKS was modi-
fied to allow an exhaustive sampling of the fragment space 
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associated to a compound. Additionally, dummy atoms were 
introduced to mark points where the compounds were broken 
down to highlight bond cuts and maintain information about 
the molecular pharmacophore. The modifications were re-
stricted to the fragmentation part of the programme suite and 
are discussed in the Section 2 part. The analysis functionality 
of molBLOCKS was retained and can be applied as presented 
by Ghersi and Singh.[19] The modified programme was used 
to fragment known drugs to determine the range of fragments 
that could be derived from known drugs. The programme 
could also have utility in designing or enhancing a fragment 
library and in the analysis of hits from a screen.
2 |  METHODS AND MATERIALS
2.1 | Increasing fragment space
To increase the fragment space created, the molBLOCKS 
suite was modified using two different approaches. First, it 
was amended to create larger and more complex fragments. 
In addition, the fragmentation rules were extended allowing 
more bonds to be cut. The former is described in this section.
The main modification of the molBLOCKS programme 
was the introduction of an exhaustive fragmentation to derive, 
for a given ligand, combinatorically all possible molecular 
fragments. Like other fragmentation methods, molBLOCKS 
generates the smallest fragments that are derived by applying 
a set of fragmentation rules. However, in some cases, it might 
be useful to create not just the smallest possible fragments 
but some intermediate fragments as well, for example in 
cases where a key pharmacophore is known to contain more 
than one functional group. Pharmacophores could still be ob-
tained by modifying the rules for each compound individu-
ally, but require the application on a compound level to make 
sure that all key fragments are derived. The fragmentation of 
large compound libraries will then require more time.
The exhaustive fragmentation is performed in two steps. 
First, all smallest fragments are generated as implemented in 
the original version using extensive fragmentation (−e flag). 
Then, these fragments are combined to larger ones through 
combinatorics, that is each smallest fragment is combined 
with its neighbouring fragment to generate larger subgroups. 
The new parameter “k” specifies how many of the smallest 
fragments should be maximally combined. If the parameter 
is set to 1, the output will be the same as using extensive 
fragmentation in the original implementation. A larger value 
results in the calculation of all fragments up to the specified 
number of combined smallest fragment. By this, also “inter-
mediate” fragments are generated. If the parameter is set to 
a very large (or negative) number, exhaustive fragmentation 
is performed so that all possible fragments for the specified 
fragmentation rules are derived. Figure 1a highlights the 
modifications to the molBLOCKS suite.
Due to these modifications, molecules can be generated 
that are equal to the input compound (or close in size) and 
might not necessarily fulfil the standard definition of a frag-
ment. Therefore, three additional parameters are introduced 
F I G U R E  1  Modifications to the molBLOCKS suite. Schematic 
explanation of the parameters introduced to modify the original 
molBLOCKS program. The figure explains the five parameters added 
as follows: (a) k for exhaustive fragmentation, (b) fragment filtering 
parameters for maximal size (m), relative size to parent ligand (s), 
and molecular weight (w), (c) x flag for highlighting of cutting points
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to filter larger fragments. First, fragments can be filtered by 
specifying the maximal number of atoms a fragment is al-
lowed to have (parameter “m”). A second filter (parameter 
“s”) allows the specification of the maximal size relative to 
the parent compound, for example a fragment is allowed to 
contain up to 60% of the atoms in the parent molecule, if the 
value is set to 0.6. A value slightly lower than 1 makes sure 
that the input compound is not returned as a fragment, and all 
possible substructures are still retrieved. Finally, the derived 
fragments can be filtered by molecular weight (parameter 
“w”). This allows, for example the removal of fragments not 
satisfying the “rule- of- three”[14] molecular weight definition 
if that is what is required. Figure 1b reports the three different 
fragment filtering methods.
2.2 | Preserving pharmacophoric 
characteristic
Additionally, the programme was modified to address the 
limitation that the fragment pharmacophore could potentially 
change compared to the parent ligand. In the original mol-
BLOCKS version, hydrogens are added to those atoms defin-
ing the bond that was broken to create the fragments. This 
approach can increase the number of hydrogen bond donors 
present, for example if the fragmentation rule was applied to 
a bond with a nitrogen and another heavy atom. This frag-
mentation approach may not reproduce the pharmacophore 
and binding interactions of compounds. To account for this, 
the programme was extended to allow highlighting of cutting 
points. A flag named “x” can be turned on to replace the added 
hydrogens with dummy atoms (asterisks) in the SMILES rep-
resentation. The asterisks in the SMILES strings represent 
a new, undefined atom having no specified atom type. By 
this approach, no assumptions are made about the identity 
of the atoms on either side of the bonds which have been 
fragmented. This is a desired functionality as it keeps the pro-
gramme straightforward, flexible and usable with any frag-
mentation rule provided as a SMARTS string. Additionally, 
the returned fragments have valid SMILES strings that can be 
used in other programmes. Figure 1c shows how fragments 
with cutting points appear schematically.
2.3 | Expanding fragmentation rules
Generating the complete molecular fragment space asso-
ciated with a given molecule cannot only be addressed by 
increasing the number of fragments through exhaustive frag-
mentation; the chemical context needs to be considered as 
well. It is necessary to use fragmentation rules that can deal 
with the complexity and immense diversity of the chemical 
space of a compound. Therefore, an extended version of the 
RECAP rules was created (called extendedRECAP) with an 
additional 16 rules (see below for download instructions), 
mostly covering bonds with sulphur, phosphate and other 
carbon atom environments. These rules were derived through 
fragmentation of a series of exemplary compounds in house. 
Although BRICS creates more fragments than the standard 
RECAP approach, the latter was used as basis to preserve 
ring structures in the fragments.
The modified molBLOCKS programme and the addi-
tional fragmentation rules extendedRECAP are made freely 
available under https://github.com/kheikamp/modified_mol-
BLOCKS. A description of how to use the programme is 
included. The programme is available as GPL C++ source 
code. It can be incorporated into in- house software, a key 
advantage over other commercial and proprietary software 
systems.
2.4 | Study goal and design
The major focal point of this study was to analyze the in-
fluence of the exhaustive fragmentation of compounds on 
the generated fragment space. The modified molBLOCKS 
programme will generate many more subgroups of input 
compounds and potentially a different representation of 
these subgroups when highlighting the cutting points. This 
study aimed to identify the changes in the fragments itself 
and the number of fragments generated per compound and 
in total. Furthermore, the analysis examined whether key 
pharmacophores of ligands could be generated using the 
extended program. For this, the three different fragmenta-
tion rules available in molBLOCKS (RECAP, BRICS, and 
CCQ), and extendedRECAP rules were used. In the anal-
ysis, only fragments containing at least five atoms were 
used (setting “−n 5”), and those that are true substructures 
of the input compounds were generated. The latter was 
achieved by constraining the fragment size relative to the 
parent structure to 99% (setting “−s 0.99”), that is the frag-
ment was only allowed to contain 99% of the atoms of the 
parent structure. The number of combined smallest frag-
ments specified through the parameter k was either set to 
1 (setting “−k 1”) to reflect standard fragmentation or to 
8 (setting “−k 8”) to derive all important subgroups. The 
empirical value 8 was identified to be appropriate in pre-
liminary in- house calculations. Finally, the fragmentation 
was performed both using the dummy atoms flag (“−x”) 
and the default of attaching hydrogens to cutting points. In 
the following, the settings of “−n 5” and “−s 0.99” were 
kept constant for all fragmentation calculations, and only 
the parameters k and x and the fragmentation methods were 
modified.
2.5 | Compound data sets
For our analysis, drug data were selected from the 
DrugBank[20] and the ChEMBL[21,22] databases and were 
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processed using KNIME.[23] From DrugBank, 1,556 com-
pounds were derived (accessed on July 14, 2015). Three 
drugs were excluded from the analysis as they contained 
repetitive units with a multiple fragment count and hence 
did not contain a SMILES representation (compound iden-
tifiers DB00707, DB00895, and DB06439). The remaining 
compounds were processed to remove salts using the default 
settings in the RDKit Salt Stripper node in KNIME and two 
additional filters for Gadolinium (Gd+3) and Silver (Ag+) 
were applied. Canonical SMILES were calculated using 
Open Babel resulting in a set of 1,550 drugs. There were 27 
drugs that consisted of more than one fragment, of which 
only three were kept, as the fragments were the same. To 
remove the multiple representations, these structures were re-
duced to its common entity. The final set of compounds from 
DrugBank consisted of 1,526 approved drugs.
From ChEMBL, 1,556 approved drugs with structure 
information were obtained (Approved Drug Data Freeze: 
November 2014, accessed on July 14, 2015). The same filter-
ing steps were applied to these drugs resulting in 1,537 drugs 
without salts (filter removed no drugs) and consisting only of 
a single structure (filter removed 19 drugs).
A unique set of drug data was derived by merging 
DrugBank and ChEMBL filtered drugs on their canonical 
SMILES calculated with Open Babel. The total number of 
2,047 unique drugs obtained was further processed by an in-
organic filter and compounds with a molecular weight larger 
than 600 Da were removed. The final set consisted of 1,762 
drugs in total having different areas of application.
3 |  RESULTS AND DISCUSSION
3.1 | Intermediate fragments generation
The fragmentation using the four different fragmentation 
rules BRICS, CCQ, RECAP and extendedRECAP, and the 
parameters specified in the Methods and Materials section 
was applied to the combined set of drugs from DrugBank and 
ChEMBL to analyze the effect of exhaustive fragmentation. 
Some of the compounds were not fragmented, either because 
the fragmentation rules did not match any part of structure 
or the generated fragments were too small and did not fulfil 
the condition of having at least five atoms. Table 1 lists the 
number of drugs that could be fragmented using the speci-
fied parameters and the number of fragments that were gener-
ated from this set. It can be seen that more compounds were 
fragmented when the combinatorial factor was set to 8. This 
means that some of the compounds generated too small frag-
ments that were filtered out when using the simple fragmen-
tation. The combinatorial fragmentation with the modified 
molBLOCKS programme, however, produced intermediate 
fragments that were large enough to pass the filter of minimal 
number of atoms in the fragments. Furthermore, the number 
of unique fragments generated by this is much larger than 
using the simple fragmentation. The same trends can be seen 
for the four different fragmentation rules and differs in the 
multiplier. The multiplier is between 20 when using RECAP 
and 120 when using the extendedRECAP rules and dummy 
atoms.
The higher number of unique fragments from the drug set 
generated by “extendedRECAP” is a result of an increasing 
number of fragments generated for each drug compound. 
There are more fragmented drugs as more fragments fulfil 
the required minimal number of five atoms. Figure 2 shows 
the number of fragments per drug as boxplots for the dif-
ferent fragmentation rules and parameters. The figure high-
lights that the distribution of the number of fragments and 
median values are comparable for all four fragmentation 
rules. Increasing the combinatorial parameter k from sim-
ple to exhaustive fragmentation increases the quartiles and 
median number of fragments per drug compound. Thereby, 
T A B L E  1  Number of fragmented drugs and generated fragments
Parameter
No. of fragmented 
drugs
No. of 
unique frags
BRICS, n = 5, k = 1, 
s = 0.99
1,564 961
BRICS, n = 5, k = 8, 
s = 0.99
1,599 56,008
BRICS, n = 5, k = 8, 
s = 0.99, x
1,599 67,546
CCQ, n = 5, k = 1, 
s = 0.99
1,462 1,121
CCQ, n = 5, k = 8, 
s = 0.99
1,543 59,081
CCQ, n = 5, k = 8, 
s = 0.99, x
1,543 69,094
RECAP, n = 5, k = 1, 
s = 0.99
1,561 1,395
RECAP, n = 5, k = 8, 
s = 0.99
1,587 28,082
RECAP, n = 5, k = 8, 
s = 0.99, x
1,587 29,992
extendedRECAP, n = 5, 
k = 1, s = 0.99
1,676 620
extendedRECAP, n = 5, 
k = 8, s = 0.99
1,709 54,888
extendedRECAP, n = 5, 
k = 8, s = 0.99, x
1,709 74,001
The table lists the number of DrugBank and ChEMBL drugs that were fragmented 
and the number of generated fragments for the four applied fragmentation rules 
BRICS, CCQ, RECAP and extendedRECAP. The parameter settings of (n = 5) 
for minimal number of atoms and (s = 0.99) for the relative maximal size were 
kept constant for all fragmentation calculations. For each rule, three different pa-
rameter settings were chosen to represent simple fragmentation (k = 1) and ex-
haustive fragmentation with (k = 8, x) and without dummy atoms (k = 8).
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the introduction of dummy atoms has only a small influence 
on the fragment frequency. The lowest increments of median 
values can be seen for the fragmentation methods CCQ and 
RECAP with an increase from one to seven and two to eight 
when applying a combinatorial factor k = 8, respectively. 
Although CCQ has the lowest median values, it also results 
in most of the outliers and highest number of fragments. 
The maximum number of fragments per compound is 3819 
when using a value k = 8 and dummy atoms together with the 
rule CCQ. This is why the second highest number of unique 
fragments is obtained using this method. More unique frag-
ments are obtained with the extendedRECAP method. Here, 
the median values of 23 (k = 8) and 24 (k = 8, x) are higher 
than for all other fragmentation methods.
The exhaustive fragmentation also has an influence on the 
top- ranked fragments per fragmentation method. Figure 3 
shows the five most frequent fragments for each of the four 
fragmentation methods and for simple and exhaustive frag-
mentation. The SMILES of the 100 most frequent reported in 
the Tables S1–S12 of the Supporting information.
F I G U R E  2  Distribution of fragments per drug. Distribution of the number of fragments per drug compound for the four different 
fragmentation rules BRICS, CCQ, RECAP and extendedRECAP. For each rule, three different parameter settings were chosen to represent simple 
fragmentation (k = 1) and exhaustive fragmentation with (k = 8, x) and without dummy atoms (k = 8)
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The figures highlight that both the introduction of the 
combinatorial factor and the dummy atoms have an influence 
on the most frequent fragments. In Figure 3a, the parame-
ter k = 8 increases the number of aliphatic atom chains for 
BRICS that are a result of combining individual atoms and 
small fragments. Highlighting the cutting points by adding 
the flag x returns a better illustration of the original molecular 
structures that were fragmented. For example, the top- ranked 
benzene ring is now separated into two structures with a dif-
ferent number of cutting points. In general, slight changes in 
the order can be seen for changing the parameters. The most 
frequent fragments obtained by the fragmentation rule CCQ 
(Figure 3b) are different to BRICS. Apart from two toluene 
fragments, all structures are aliphatic chains mostly contain-
ing nitrogen or oxygen. The different parameter settings have 
a strong impact on the top- ranked fragments and change their 
order totally. Not shown here is that many additional frag-
ments created with BRICS are due to the separation of ring 
structures and their recombinations. They are ranked lower 
as they are less common in the data set. Figure 3c shows the 
most frequent fragments for the RECAP method. Increasing 
the combinatorial factor k has almost no influence on the five 
most frequent fragments. The introduction of cutting points 
reduces the frequency of each fragment and results in com-
plex structures and more carbon chains. Finally, Figure 3d 
reports the top five fragments for the extendedRECAP frag-
mentation method. The exhaustive fragmentation results in 
more aromatic ring structures that are ranked highest. As a 
result, the two approaches simple and exhaustive fragmenta-
tion differs from rank two on. Using exhaustive fragmenta-
tion and dummy atoms has a strong impact on the fragment 
frequencies compared to simple fragmentation. The top four 
fragments are all benzene structures with a different num-
ber and distribution of cutting points. The fifth most frequent 
structure is toluene. To analyze the impact of the introduced 
dummy atoms, the fragment cutting points are discussed in 
the following section 3.2.
3.2 | Highlighting of cutting points
The previous analysis has already shown that the use of 
dummy atoms results in more generated fragments. The ques-
tion is whether these fragments contain more information 
about the structure they originate from. Figure 4 shows three 
examples of fragments generated with the extendedRECAP 
F I G U R E  3  Top- ranked fragments. The structures of the five most frequent fragments and the number of occurrences (Num) are reported. 
Data are shown for simple fragmentation (k = 1) and exhaustive fragmentation with (k = 8, x) and without dummy atoms (k = 8) for the four 
fragmentation methods BRICS (a), CCQ (b), RECAP (c) and extendedRECAP (d)
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method and a combinatorial factor of 8. In one case, dummy 
atoms are used in the SMILES representation to highlight 
cutting points and in the other cases, they are suppressed and 
hydrogen atoms are added instead. This might change the 
properties of the fragments with respect to the original mol-
ecule as explained in Section 2.
Figure 4a reports the various representations of the frag-
ment benzene resulting from the different parameter settings. 
In total, 811 benzene fragments are generated from the drug 
data set using the extendedRECAP fragmentation without 
dummy atoms. Turning on the flag x results in eleven dif-
ferent representations of the benzene structure with one to 
five cutting points. Additionally, the total number of differ-
ent fragments increases to 957. This means that some drugs 
contain more benzene rings with different number and dis-
tributions of bonds that were previously mapped to the same 
fragment and are now separated into their specific fragment 
patterns. Figure 4b shows the different morpholine struc-
tures from the fragmentation. Thereby, 16 fragments were 
generated from the drug set for both approaches. The figure 
highlights why the cutting points increase the information 
about the original compound. Two of the four fragments de-
rived with dummy atoms have cutting points at the nitrogen 
atom. This information is not available when the flag x is 
turned off which incorrectly increases the number of hydro-
gen bond donors in these cases. This effect is also illustrated 
in Figure 4c reporting different sulphonamide fragments 
from the data set. The 23 sulphonamide structures generated 
without dummy atoms are separated into four fragments with 
diverse cutting point patterns. Here, both nitrogen atoms can 
be part of the bond that was cut or a terminal atom in the 
original molecule.
F I G U R E  4  Comparison of fragments with and without cutting points. Fragments generated with dummy atoms are contrasted with fragments 
generated without cutting points. All fragments are generated with the extendedRECAP and exhaustive fragmentation. The comparison is reported 
for the three examples: benzene (a), morpholine (b) and sulphonamide (c)
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3.3 | Application of weight filter
In addition to the size filter, the modified molBLOCKS pro-
gram allows the application of a weight filter to the generated 
fragments. This could be used to reduce the set of fragments 
to those fulfilling the “rule- of- three.”[14] The rule- of- three 
proposes that the ideal fragment should fulfil the conditions 
of a molecular weight <300, ClogP ≤3, the number of hy-
drogen bond donors and acceptors each ≤3, and the number 
of rotatable bonds ≤3. In the following, these filters are ap-
plied separately and together to analyze the number of unique 
fragments. The fragments set were generated with exhaus-
tive fragmentation (−k 8) using the extendedRECAP method. 
Figure 5 reports the number of fragments for the sets with and 
without cutting points. Thereby, the filters have a different 
effect on the two fragment sets. The application of the weight 
filter in both cases almost halves the size of the fragment set. 
When no dummy atoms are used, almost no reduction is ob-
tained applying the hydrogen bond donor filter. The best filter 
in this case is the hydrogen bond acceptor. However, the size 
of this set is still more than double of rule- of- three compli-
ant fragment set. The reduction in the fragments with cutting 
points is comparable for the weight and hydrogen bond donor 
filter and keeps the highest number of unique fragments. The 
best reduction is achieved applying the rotatable bond filter. 
Summarizing, the exhaustive fragmentation results in sets of 
fragments that usually do not comply with the rule- of- three. 
However, the generated sets contain distinct fragments and 
the key components for bioactivity are generated as analyzed 
in the following section.
3.4 | Identification of key fragments
As stated earlier, the FBDD methodology is based on the as-
sumption that fragments are engaged in the same interactions 
with the target protein even when other parts of the ligands 
are removed. In this part, we analyze whether those conserved 
fragments retaining the binding mode can be generated with 
exhaustive fragmentation. For the analyses, example struc-
tures are taken from a recent analysis and study performed 
by Kozakov et al.[24] Their study introduces a simple meas-
ure to determine how fragments interact with binding energy 
hot spots to identify the proteins and fragments most suit-
able for screening. We chose three representative examples 
from the eight case studies published and tested whether the 
fragments retaining their initial binding mode were gener-
ated with the exhaustive fragmentation. The results are com-
pared to the simple fragmentation approach from the original 
molBLOCKS programme generating the smallest fragments 
only, see above. For each example, the best fragments from 
the simple and exhaustive fragmentation were chosen based 
on the closest similarity to the key pharmacophore, meaning 
the fragments were selected to incorporate as many points 
of interaction with the target as possible (as described by 
the X- Ray structure, see below). This was considered as 
the portion of the molecule driving the molecular recogni-
tion event with the target leading to the biological response. 
Methodologically, the generated fragments were ranked by 
number of atoms and by the overlap of the SMILES strings. 
The exhaustive fragmentation was able to generate the mini-
mum fragment that retains the correct binding pose.
Figure 6a,b report the case study of inhibitors of the in-
teraction between VHL protein and HIF- 1α. Figure 6a shows 
the interaction of the inhibitor with the protein structure ob-
tained from PDB entry 3ZRC. On the top, Figure 6b shows 
the inhibitor that binds to VHL and blocks its interaction with 
the transcription factor HIF- 1α. van Molle et al. determined 
that the fragment N- Hyp on the right binds with a fully con-
served position in the main hot spot of VHL.[25] Applying 
simple fragmentation using the extendedRECAP method, 
we can generate a subgroup of the optimal fragment, but 
not the whole fragment. This is caused by the following two 
F I G U R E  5  Filtering of generated 
fragment sets. The application of no filters 
and rule- of- three filters on fragment set 
generated using exhaustive fragmentation 
and the extendedRECAP fragmentation 
rules is compared. The filters include a 
weight filter <300, ClogP ≤3 (here: xlogP 
is used), hydrogen bond donor (HBondD) 
≤3, hydrogen bond acceptor (HBondA) ≤3, 
number of rotatable (non- terminal) bonds 
(RotBond(nT)) ≤3
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aspects: (i) the simple fragmentation only returns the small-
est fragments and (ii) the smallest fragment results from the 
application of all fragmentation rules in extendedRECAP. 
This includes, for example a rule cutting the bond of a cy-
clic amine and any other atom and a rule for breaking the 
bond of carbon in a ring structure with any atom, resulting in 
the shown subgroup. However, N- Hyp. can be returned using 
exhaustive fragmentation due to the combination of several 
subfragments, that is the smallest fragments are recombined 
to larger fragments including N- Hyp. This result is represen-
tative for other case studies published in Kozakov et al., like 
for example, the case study of inhibitors of SH2 domain of 
pp60Src.
The second case study considered here concerns thrombin 
inhibitors shown in Figure 7a,b. The inhibitor reported was 
based on the chlorophenyl fragment on the right top (high-
lighted in blue). The fragment binds in the same position of 
the main hot spot in the S1 pocket of thrombin. Again, the 
simple fragmentation only retrieves a subgroup of this frag-
ment, a benzene ring, whereas the exhaustive fragmentation 
generates the whole chlorophenyl fragment. The observed 
behaviour can again be explained by the internal nature of the 
simple fragmentation approach generating the smallest frag-
ments only and the advantage of the recombination of these 
fragments in exhaustive fragmentation. The authors also re-
port on a second fragment (highlighted in purple) that binds 
to the second- ranked hot spot of thrombin located in the S4 
pocket. The benzene ring is again the closest fragment that 
can be generated with the simple fragmentation. The exhaus-
tive fragmentation is able to almost fully create this fragment. 
Missing parts include the carbon side chains on the benzene 
ring and nitrogen. However, the whole fragment can be built 
by further increasing the combinatorial factor that was set 
to 8 here. The authors also discuss that this fragment has a 
molecular weight of 392 and would not be considered a true 
fragment based on the rule- of- three. Therefore, they suggest 
the use of slightly smaller subfragments of the original frag-
ment structure. These smaller fragments could be generated 
with the current parameter settings.
Finally, Figure 8a,b report on the case study for the chiti-
nase inhibitor argifin. The ligand on the top left in Figure 8b 
is the natural cyclopentapeptide argifin that inhibits 
F I G U R E  6  Case study for the 
identification of key fragments: VHL 
protein and HIF- 1α. Simple and exhaustive 
fragmentation are contrasted to analyze  
how they reproduce conserved fragments 
from an inhibitor of the interaction between 
VHL protein and HIF- 1α (PDB code 
3ZRC). (a) Fragmentation of the ligand. 
(b) Key interactions between ligand and 
protein. The 2D diagrams illustrating the 
protein–ligand interactions were generated 
using MOEa 
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chitinase. The two observed fragments are shorter molecules 
both containing the dimethylguanylurea moiety. Andersen 
et al. showed that these two fragments on their own bind in 
the same position as argifin.[26]  The simple fragmentation is 
not capable of generating a fragment containing at least five 
atoms that are a subfragment of argifin. Therefore, in this 
example, the minimal number of atoms in a fragment was 
reduced to two to generate a small subgroup of the ligand. 
The figure also illustrates the three fragments that were gen-
erated using exhaustive fragmentation. They are similar to 
the two fragments described by Andersen et al. One frag-
ment contains the large ring structure as no applied frag-
mentation rule is able to break the ring. For this, enhanced 
fragmentation rules have to be defined. Interestingly, the 
ring structure cannot be cut either utilizing BRICS (data not 
shown), which highlights the need of other fragmentation 
rules for ligands in this context.
The three examples show that the modifications of the 
molecular fragmentation programme molBLOCKS result in 
fragments that are closer to the key pharmacophores of com-
pounds than those created by other standard fragmentation 
systems only generating the smallest fragments. The list of 
generated fragments contains the minimal pharmacophoric 
elements that are responsible for the interaction of the com-
pound and the biological target. This is the key advantage 
over other fragmentation approaches.
F I G U R E  7  Case studies for the 
identification of key fragments: thrombin 
inhibitors. Simple and exhaustive 
fragmentation are contrasted to analyze  
how they reproduce conserved fragments 
from thrombin inhibitors (PDB code  
2C8X). (a) Fragmentation of the ligand. 
(b) Key interactions between ligand and 
protein. The 2D diagrams illustrating the 
protein–ligand interactions were generated 
using MOEa
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4 |  CONCLUSION
Here, we have presented a modified fragmentation program 
that can generate an exhaustive sampling of the fragment 
space associated to a given molecule. We adopted the recently 
published program suite molBLOCKS and extended its func-
tionality to derive more fragments from a compound structure 
and not just the smallest, terminal subgroups. We introduced 
an additional parameter to deal with the capping problem by 
highlighting the bond cuts in the returned fragments. This 
extension does not affect the possibility to define new frag-
mentation rules for different compound spaces as provided 
by the original program suite. Further introduced parameters 
allow filtering of the fragment set by their size and molecular 
weight. The modifications were limited to the fragmentation 
program from molBLOCKS to keep the functionality of frag-
ment clustering and statistical detection of prominent frag-
ments provided by the analysis method.
The new fragmentation programme was applied to a set 
of drug compounds to analyze the effect of the modifications 
F I G U R E  8  Case studies for the 
identification of key fragments: the chitinase 
inhibitor argifin. Simple and exhaustive 
fragmentation are contrasted to analyze 
how they reproduce conserved fragments 
generated from the chitinase inhibitor argifin 
(PDB code 1W9V). (a) Fragmentation of the 
ligand. (b) Key interactions between ligand 
and protein. The 2D diagrams illustrating 
the protein–ligand interactions were 
generated using MOEa
   | 13HEIKAMP Et Al.
on the generated fragments. This exhaustive fragmentation 
algorithm was able to fragment more drugs being broken 
down and gave much larger sets of unique fragments. This 
is because more fragments are derived on a compound level. 
Furthermore, exhaustive fragmentation yielded additional 
fragments and fragment frequencies compared to simple 
fragmentation. The use of dummy atoms to highlight cutting 
points resulted in fragments with higher information con-
tent as previously overlapping fragments can be separated 
into fragments with different bonding patterns. Although 
the fragments derived by exhaustive fragmentation did not 
necessarily fulfil the definition of a true fragment based on 
the “rule- of- three,” the generated set of fragments is diverse 
and the fragments most suitable for screening can be calcu-
lated as opposed to the standard fragmentation.
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